Iziphi Izivivinyo Ukuhlola I-Mass Ovarian for Cancer?

Izivivinyo ezihlanganisa Ingozi ye-Malignancy Index Ukuhlola iziMizi ze-Ovarian

Uma udokotela wakho ethola isisindo somzimba we-ovarian ngemuva kokubuka i-ultrasound, noma uzwa omunye ekuhlolweni, yiziphi amathuba ukuthi yini etholakele ngumdlavuza we-ovarian?

Ungazi kanjani Uma iMisa Yakho Ye-Ovarian i-Ovarian Cancer?

Uma unesisindo endaweni lapho ama-ovari akho akhona khona, ungase uzwe ukwesaba ngaphezu kokudideka kakhulu. Kungaba yini?

Ungase uzizwe ukwesaba kakhulu njengoba uqaphela udokotela wakho engazi ukuthi ubukhulu bakho bungaba nomdlavuza noma cha. Akufanele yini azi? Ingabe kukhona into akutshelanga yona?

Ukuze ususe okunye ukwesaba kwakho, kuyinto evamile ukuba odokotela baxakeke ngobuningi be-pelvic esifundeni sama-ovari (okuthiwa "i-adnexal mass" uma uzwa lelo gama.)

Ngesikhathi esifanayo ukuthi odokotela bangenalo umqondo wokuthi inqwaba ye-adnexal ekhanda lakho ingaba nomdlavuza, ithuba lokuba "okungalungile" -ukusebenza ngaphambi kokuthola umbono ongcono-kuhambisana ngokufanayo. Kungaba nezinkinga ngale ndlela: Ingozi kokuhlinzwa ngokunganele uma ngempela unomdlavuza, futhi ubungozi bokuhlinzwa okungadingekile kanye nokukwazi ukubhekana nezinkinga ngaleyo ndlela yokuhlinzeka uma ungenayo umdlavuza.

Ingabe Usengozini Ye-Ovarian Cancer?

Sinomqondo wokuthi ubani osemngciphekweni we-ovarian umdlavuza, kodwa lokhu kukhulunywa kakhulu ukuze ungaxoshi ingozi yakho yomdlavuza we-ovari uma ungenayo izici eziyingozi.

Kukhona isizathu sokuthi umdlavuza we-ovarian usungulwe umbulali othulile . Ngokuvamile kubangela izimpawu ezimbalwa kuze kube yilapho umdlavuza usuqhubekela phambili, futhi noma ubani, kungakhathaliseki ukuthi yiziphi izinto eziyingozi, angase abe engozini yokuthuthukisa lesi sifo.

Uma u-postmenopausal, usengozini enkulu. Amanqamu amaningi e-ovarian ayenzeka kubafazi asebekhulile (nakuba kungase kwenzeke kwabesifazane abasebasha noma ngisho nezingane.) Ngesikhathi esifanayo, izixuku ze-adnexal kubesifazane abasha zivamile futhi zivame ukufika.

Ama-Cysts avamile ngaphambi kokuya esikhathini sokuya esikhathini, kanti inqwaba ebonakala emaphoyiseni ase-post-menopausal ayinakukwazi ukuhamba yedwa. Khumbula, noma kunjalo, ukuthi noma ngabe usudlulile esikhathini esizayo, ungase ube nesisindo esingenomdlavuza.

Izimpawu zomdlavuza we-ovari zingase zibandakanye ukuvinjelwa nesisindo somzimba, ubuhlungu ngesikhathi socansi, noma ukuguquka kwemikhuba yezinyosi. Izici zengozi zihlanganisa ukukhuluphala, ukuba nomlando womndeni webele, i-ovarian, noma umdlavuza we-colon, nokusetshenziswa kwangaphambili kwezidakamizwa ezithile zokuzala noma ama-hormone alternative therapies. (Funda kabanzi mayelana nomdlavuza wesibeletho se-ovarian .)

Ukubaluleka kokwazi ukuthi iMisa i-Ovarian Cancer

Ngokuqinisekile kubalulekile ukwazi ukuthi ubuningi obunayo yini umdlavuza wakho ukuthula kwengqondo. Kodwa ngomdlavuza we-ovarian ikakhulukazi, ukwazi ukuthi umdlavuza ungase ube khona noma ubaluleke kakhulu kunamanye amaningi kansa.

Uma ukuhlinzwa kuzokwenziwa umdlavuza we-ovari, udokotela ohlinzayo udinga ukulungele inqubo ende uma kudingeka. Ukuhlinzwa ngokucophelela kungaba nomthelela oqondile ekusindeni. Ngesikhathi esifanayo, ucwaningo luye lwathola ukuthi ukuhlinzwa okulukhuni ( ukuhlinzekwa kwe-cytoreduction yomdlavuza we-ovarian ) kunomqondo ongcono kakhulu uma kwenziwa ochwepheshe emdlalweni we-ovarian (nge-gynecologic oncologists) esikhungweni esenza umthamo omkhulu walezi zindlela zokuhlinza, kunokuba ngokuvamile izifo zemizimba ezenza okuncane kulezi zindlela zokuhlinzwa.

Sekujwayelekile kakhulu ukuthi udokotela ohlinzayo aqaphele ukuthi umdlavuza we-ovarian ozodinga ukuhlinzwa okulukhuni futhi okude kuvele ngemuva kokuhlinzwa.

Izindlela Zasetshenziselwa Ukunquma Ingozi Yokuhlambalaza (Ukuhlukanisa uBenign kusuka Emassesheni Ase-Malignant Ovarian)

Njengoba kubaluleke kakhulu ukuzama ukuhlukanisa i-ovarian cancer kusuka kwamanye ama-ovarian ngaphambi kokuhlinzwa, isifundo se-2016 sazama ukuhlola amathuluzi esikhona manje, futhi sibheke ikhono labo lokuhlukanisa ama-cancer kusuka emasimini angenayo umdlavuza.

Kuwusizo ukuqaphela amagama ambalwa uma ubheka lezi ziphumo zokutadisha.

Ukuzwela kuyisilinganiso esetshenziselwa ukukhombisa ukuthi uphumelele kanjani ukuhlolwa ekutholeni umdlavuza; ukuthi kaningi kangakanani lapho kungabonakala khona labo bantu abanesifo. Isibonelo, ukuvivinywa nokuzwela kwamaphesenti angama-90 kuzokwazi ukuthola amaphesenti angama-90 kwangu-khansa.

Kubalulekile ukuthi ungahlolisisi izimo futhi, njengoba ukuxilongwa ngokweqile kungaholela ekuhlinzekeni okungadingekile kanye nokwelapha. Okucacile kuyisivivinyo esiza ukuchaza ukuthi ngokuvamile ukuxilongwa ngokweqile kungenzeka kanjani ngokuhlolwa. Okucacile kubuza umbuzo, "Kangaki, uma umuntu engenaso lesi sifo, ingabe ukuhlolwa kungabi nhlobo?"

Izivivinyo zamanje ezingasetshenziselwa ukuhlola inqwaba yama-ovari zihlanganisa:

Ithebula elilandelayo libonisa imiphumela eqhathanisa nalezi zinyathelo ezine ezibandakanya ukuzwela kwazo nezici ezithile.

Izivivinyo Ukuhlola Ukuthi iMisa i-Ovarian Cancer

Ukuhlolwa Ukuzwela Okucacile
Ukuhlola okungaqondakali Amaphesenti angu-93 Amaphesenti angu-89
Imithetho Elula * Amaphesenti angu-93 Amaphesenti angu-80
I-LR2 * Amaphesenti angu-93 Amaphesenti angu-84
Ingozi ye-Malignancy Index Amaphesenti angu-75 Amaphesenti angu-92

* I-International Ovarian Tumor Analysis (IOTA) imithetho elula esekelwe i-ultrasound (imithetho elula) kanye ne-IOTA yesimo sokuguqula imodeli 2 (LR2)

Isiphetho sezifundo zakamuva ukuthi ukuhlanganiswa kokuhlola okuzithobayo kanye nemithetho elula kunganikeza ukulinganisa okungcono kakhulu ukuthi ngabe isisindo somzimba se-ovarian singumdlavuza noma cha.

Ingozi ye-Malignancy Index ye-Ovarian Cancer

Odokotela abaningi basebenzisa i-Risk of Malignancy Index (RMI) ngedwa noma bahlanganiswe "nokuhlolwa okuzithobayo" kanye nokutholakala kwe-ultrasound ukusiza ukuhlunga ama-ovarian. Kunezinguquko eziningana ze-RMI, futhi zonke zibikezela ingozi yokulimaza y (ingozi ukuthi isisindo sinomdlavuza). Le nguqulo ihlolwe izikhathi eziningana ngabacwaningi abahlukahlukene eminyakeni edlule.

Kunezici ezintathu eziyinhloko ezisetshenziselwa ukucacisa i-RMI. Lokhu kufaka:

Ingozi ye-Malignancy Formula ye-Ovarian Cancer

Uma unesithakazelo ekutholeni ezobuchwepheshe, ifomula eyisisekelo yengozi ye-malignancy index (RMI) yile:

U umele amaphuzu e-ultrasound, kusuka ku-0 kuya ku-5 M. Isikripthi sokunqamuka kokumisa lapho ku-1 kubelwe khona labo aba-premenopausal, futhi-3 kubelwe kulabo abathumela i-post-menopausal. Isici sokugcina yinani lezinombolo zezinga lakho le-CA-125; inani lama-35 noma eliphansi libhekwa njengokujwayelekile. Uvele ukwandisa amanani we-U, M ne-CA-125 ukuthola i-RMI.

Ukuqonda Ingozi Yakho Ye-Malignancy (RMI) Isilinganiso - Kusho ukuthini?

I-RMI isikolo esingaphezulu kuka-200, sibalwa ngale ndlela, kubhekwa njengokusola. Uma kudlula 250, ithuba lokuthi lokho unayo ngumdlavuza kakhulu. Kodwa-ke, leli gama eliyisisekelo liyi "ithuba." Khumbula ukuthi le nkomba isiza ukuhlunga izinto, kodwa ayiqinisekisi indlela eyodwa noma enye ukuthi unomdlavuza ngokuqinisekile noma cha. Isibonelo, uma ungaphansi kweminyaka engu-50 futhi une-endometriosis, noma unezinye izizathu ze-CA-125 ukuba ziphakanyiswe, i-RMI ingahle ibe phezulu. Ngakho-ke, ungase ungabi nomdlavuza. Ngakolunye uhlangothi, ezinye zegciwane azikhiqizi i-CA-125, ngakho-ke i-RMI ingahle ibe yikhohlisa.

Izinyathelo Ezilandelayo Ekuhloliseni I-Canary Ovarian Cancer

Udokotela wakho angasebenzisa ukuhlolwa okukodwa noma ngaphezulu ngenzansi ukuze azame futhi anqume ukuthi umthamo wakho we-ovarian ungumdlavuza. Ukunquma lokhu kusengaphambili kungakusiza ukwazi ukuthi i-oncologist yezinkinga zokubeletha kufanele itholakale yini ekuhlinzekeni kwakho. Uma kungenzeka ukuthi ubuningi bakho buzoba nomdlavuza, okubaluleke nakakhulu lokhu kuzoba khona.

Imikhawulo yezinqubo zokuhlola izibalo ze-Ovarian Mass

Kubalulekile ukuqaphela ukuthi kunezilinganiso ngisho nokuhlolwa okuhle kakhulu okusetshenziselwa ukubikezela ukuthi ngabe umdlavuza we-ovariya ungaba yini noma cha. Wena nodokotela wakho kuzodinga ukuhlanganisa imiphumela yanoma yiluphi lwalezi zivivinyo ngolunye ulwazi, njengezimpawu zethu kanye nanoma yiziphi izinto ezinobungozi obunomdlavuza we-ovarian. Ngamanye amazwi, kubalulekile ukukubuka njengomuntu, kunanoma yiziphi izinombolo ezithile uma unquma ngezinyathelo ezilandelayo ekuhloleni ukwelashwa ..

Ukubhekana Nengabe Unesisindo Se-Ovarian Esimisayo

Kubalulekile ukuthi ube nengxoxo egcwele nodokotela wakho uma unesisindo sama-ovari. Ngokusekelwe emiphumeleni ethuthukisiwe phakathi kwalabo abanomdlavuza we-ovarian lapho i- oncologist yezinkinga zokubeletha ikhona khona, kanye nemiphumela emihle ezindaweni ezenza lezi zinqubo eziningi, imibono yesibili ne-oncologist gynecologic ingase ihlakaniphe kungakhathaliseki ukuthi imiphumela yanoma yikuphi ukuhlolwa noma izici eziyingozi.

Thatha isikhathi sokufunda ngesimo sakho. Cela futhi wamukele ukwesekwa kwabakuzungezile. Ingozi yokufa ngomdlavuza we-ovari isisa kakhulu kakhulu, futhi ukuba ngummeli wakho siqu ekunakekeleni kwakho kuyinto eyodwa ongayenza yona ongakwazi ukuthuthukisa umphumela wakho.

Imithombo:

Kaijser, J., Bourne, T., Valentin, L. et al. Ukuthuthukisa Amasu Wokuthola I-Ovarian Cancer: Isifinyezo se-International Ovarian Tumor Analysis (IOTA) Izifundo. I-Ultrasound ku-Obstetrics ne-Gynecology . 2013. 41 (1): 9-20.

Minig, L., Padilla-Iserte, P., noCosterrero. Ukubheka kwama-Gynecologic Oncologists ukuhlinzeka ngezinga eliphakeme lokunakekelwa kwabesifazane nge-gynecological cancer. Imingcele e-Oncology . 2015. 5: 308.

Izinyathelo, E., Kaijser, J., Kruitwagen, R. et al. Ukuhlola okuhloswe ngokumelene nama-Ultrasound Models ukuze uhlolisise i-Ovarian Cancer: Ukubuyekezwa okuhlelekile kanye nokuhlaziywa kwe-Meta-Analysis. I-European Journal of Cancer . 2016. 58: 17-29.

Stuart, G., Kithener, H., Bacon, M. et al. 2010 I-Gynecologic Cancer InterGroup (GCIG) Isitatimende Sokuvumelana Sokuhlolwa Kwemitholampilo Emdlalweni We-Ovarian: umbiko ovela kwiNgqungquthela yesine ye-Ovarian Cancer Consensus. I-International Journal ye-Cancer Gynecologic . 2011. 21 (4): 750-5.